Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691210 · ClinicalTrials.gov registry record · Phase 1
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00691210 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 40 participants.
The verdict
NCT00691210, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of a combination of two anticancer medicines, called vorinostat and etoposide, with a high dose of a vitamin called niacinamide. These medications will be tested at different dose levels. The investigators want to find out what effects, good and/or bad, it has on patients and their recurrent lymphoma. The first two drugs, vorinostat and niacinamide, suppress survival signals that lymphoma cells depend on. The third drug, etoposide can kill sensitive lymphoma cells alone or in combination with other chemotherapy drugs. Vorinostat is an anticancer agent that been approved by the Food and Drug Administration for use in cutaneous T-cell lymphoma. It is being evaluated in this study in combination with other anticancer medicines for use in other types of lymphoma. Vorinostat's use in combination with anticancer regimens is experimental. Niacinamide is a vitamin that is investigational or experimental when given at high doses as an anticancer agent. Niacinamide has not yet been approved by the Food and Drug Administration for use in lymphoma. Etoposide has been approved by the Food and Drug Administration for use in aggressive non-Hodgkin's lymphoma. However, the way it will be given in this clinical study is experimental.
Interventions
- DRUG Etoposide
- DRUG Vorinostat
- DRUG Niacinamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-06 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00691210
The ClinicalTrials.gov registry entry for NCT00691210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Etoposide is the first listed.
NCT00691210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00691210 about?
NCT00691210 is a clinical study titled "Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies". The purpose of this study is to test the safety of a combination of two anticancer medicines, called vorinostat and etoposide, with a high dose of a vitamin called niacinamide. These medications will be tested at different dose levels. The investigators want to find out what effects, good and/or bad...
What is the current status of trial NCT00691210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-06. Estimated completion is 2015-03.
What interventions are being tested in trial NCT00691210?
The interventions under investigation include: Etoposide (DRUG), Vorinostat (DRUG), Niacinamide (DRUG).
Who is sponsoring clinical trial NCT00691210?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.